Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash.
Continue reading this article with a Barron’s subscription.
Bristol Myers to Acquire RayzeBio in Deal Valued at $4.1 Billion
Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash.
Continue reading this article with a Barron’s subscription.